Comparing Long-Term Survival Outcomes for Muscle-Invasive Bladder Cancer Patients Who Underwent with Radical Cystectomy and Bladder-Sparing Trimodality Therapy: A Multicentre Cohort Analysis

Table 4

Proportional hazard regression model for OS and DSS of MIBC patients by treatment time and treatment modality.

Time by modality		No. of patients	Overall survival (OS)		Disease-specific survival (DSS)
			HR	95% CI	HR	95% CI
1 year	RC-MIBC cohort	891	1.00 [reference]		1.00 [reference]
	TMT-MIBC cohort	891	1.07	0.84-1.36	1.11	0.89-1.44
5 years	RC-MIBC cohort	891	1.00 [reference]		1.00 [reference]
	TMT-MIBC cohort	891	1.26	1.01-1.53	1.30	1.04-1.59
10 years	RC-MIBC cohort	891	1.00 [reference]		1.00 [reference]
	TMT-MIBC cohort	891	0.92	0.71-1.26	0.99	0.80-1.35

Analyses were based on the Cox PH regression. All baseline covariates were well balanced in the propensity score-matched sample according to demographic and clinicopathological characteristics. Therefore, only treatment information was controlled for in the final Cox PH regression model. OS: overall survival; DSS: disease-specific survival; HR: hazard ratio; CI: confidence interval; RC: radical cystectomy; TMT: bladder-sparing trimodality therapy; MIBC: muscle-invasive bladder cancer.